EIC commits €79.3 million to 34 Transition projects as Europe pushes lab breakthroughs toward market
- ›The European Innovation Council selected 34 EIC Transition projects and allocated a total of €79.3 million.
- ›Grants are worth up to €2.5 million each and target maturation and market readiness of deep tech originating from Pathfinder, FET or ERC Proof of Concept results.
- ›The call combined open funding and targeted challenges on green digital devices, clean energy systems integration and RNA therapies and diagnostics.
- ›Selected projects span 17 EU member states and associated countries and include technologies from bio-cementation to wafer-scale metamaterial integration and RNA delivery platforms.
- ›EIC Transition winners receive access to Business Acceleration Services and a fast track route to the EIC Accelerator but commercial success will still require follow-on investment, regulatory work and scale-up.
EIC backs 34 Transition projects with €79.3 million to push lab innovations toward market readiness
The European Innovation Council announced on 8 February 2023 that it has selected 34 projects from the September 2022 EIC Transition call and allocated a combined €79.3 million in Horizon Europe grant funding. Individual Transition grants can be worth up to €2.5 million. The call mixed open funding with three targeted challenge strands: green digital devices, integration of clean energy technologies, and RNA-based therapies and diagnostics for complex or rare genetic diseases.
Numbers, scope and selection
The successful proposals were chosen from a larger pool of eligible submissions. The selected teams come from 17 EU member states and Horizon Europe associated countries. The distribution across the call modalities was: 27 projects funded under open funding, 4 projects under the Green digital devices challenge, 2 projects under the RNA-based therapies and diagnostics challenge, and 1 project under Process and system integration of clean energy technologies. Each selected project will use funding to mature technology results from earlier research activities and to develop a business case for future commercialisation.
Representative projects and technical context
The EIC highlighted several exemplar projects from the selected cohort. These capture the variety of technological approaches and sectors that the Transition instrument is intended to de-risk and ready for commercial uptake. Below are the projects the Commission singled out and additional context to help judges their potential and remaining hurdles.
Why EIC Transition matters and how it fits the European innovation ecosystem
The EIC Transition stage is a deliberate bridge between early high-risk research and commercialisation. It is meant to take outputs from EIC Pathfinder, FET or ERC-funded projects and validate them in environments that approximate real-world use. The funding is non-dilutive grant support accompanied by access to the EIC Business Acceleration Services. Selected projects can also use a fast track to apply to the EIC Accelerator for blended grant and equity support when they are ready to scale. For Europe's innovation policy, Transition aims to increase the conversion rate of frontier research into investable companies and products and to strengthen strategic autonomy in deep tech fields.
What to watch and remaining obstacles
EIC Transition grants reduce technical and early market risk but do not guarantee commercial success. The most common bottlenecks after Transition stage are fundraising for scale, industrial partnerships for manufacturing, regulatory clearances especially in medical and energy domains, and supply chain constraints for critical materials. Intellectual property protection and freedom to operate are also critical. For many of the projects selected, reaching the market within a typical venture timeframe will depend on the ability to attract private co-investment and to demonstrate repeatable performance at scale.
The EIC architecture offers a route to blended public-private funding via the EIC Accelerator and the EIC Fund, but companies often still need multiple funding rounds, anchor customers, and integration partners. Observers should watch whether the Transition cohort successfully uses BAS to secure industrial pilots, procurement leads or follow-on finance and whether the Challenge-targeted projects translate into policy-relevant demonstrators that help Europe reduce strategic dependencies in critical tech.
Selected EIC Transition projects from the September 2022 cut-off
The table below reproduces the list of projects and the recommended budgets published by the EIC. Budgets are the recommended grant amounts for each selected Transition project and reflect the typical up to €2.5 million ceiling per project.
| Proposal Acronym | Proposal Title | Coordinating Organisation | Country Coordinator | Duration (months) | Recommended Budget |
| BionicVEST-2 | EUROPEAN DEVELOPMENT OF A FIRST COMMERCIAL BIONIC VESTIBULAR IMPLANT FOR VESTIBULAR DYSFUNCTION - 2 | COCHLEAR BENELUX NV | BE | 36 | 2.498.937,50 € |
| 3DPRINTOPTIXMARKET | 3D Printed Micro-Optics to the Market | Printoptix GmbH | DE | 36 | 2.496.602,75 € |
| LiveSen-MAP | Real-time nutrient sensing for mapping fertilizer needs | TECHNISCHE UNIVERSITAET MUENCHEN | DE | 36 | 2.499.955,00 € |
| MagSense | Hyperpolarized NMR made simple | NVISION IMAGING TECHNOLOGIES GMBH | DE | 24 | 2.451.913,75 € |
| SPINNODE | SpiNNaker on the Edge | SpiNNcloud Systems GmbH | DE | 24 | 2.500.000,00 € |
| SUPREME | Superconductor-Based Readiness Enhanced Magnetoplasmadynamic Electric Propulsion | NEUTRONSTAR SYSTEMS UG | DE | 30 | 2.499.995,75 € |
| GLASS | Green Laser-Assisted Surface Structuring Biomimetic | EL | 30 | 2.498.945,00 € | |
| CARxALL | Next generation, off-the-shelf CD1a/CCR9-directed CAR immunotherapy for relapse/refractory T-cell acute lymphoblastic leukemia | ONECHAIN IMMUNOTHERAPEUTICS | ES | 36 | 2.497.500,00 € |
| HDLN | High-Density Lithium Niobate Photonic Integrated Circuits | VLC PHOTONICS SL | ES | 30 | 1.549.111,25 € |
| QSTACK | Low-power consumption, heavy-metal-free wide-spectrum image sensors for mass-market computer vision applications | QURV TECHNOLOGIES SL | ES | 24 | 2.370.937,50 € |
| RoCCQeT | Real-World Commercial Coherent Quantum Annealing Technology | QILIMANJARO QUANTUM TECH SL | ES | 24 | 2.495.000,00 € |
| SOIL2POWER | SOIL microbial fuel cells TO (2) POWER precise irrigation systems. | ARKYNE TECHNOLOGIES SL | ES | 36 | 2.499.812,50 € |
| TraffikGene-Tx | TraffikGene-Tx: Targeted Peptide Carriers for RNA Delivery | UNIVERSIDAD DE SANTIAGO DE COMPOSTELA | ES | 36 | 2.499.000,00 € |
| PeptiCHIP | Pre-clinical validation and demonstration of PeptiCHIP: an immunopurification microfluidic device and software for (neo)antigen identification and prioritization | Valo Therapeutics Oy | FI | 24 | 2.226.280,00 € |
| SoCool | Solid-State Cooling Technology for Cryogenic Devices | TEKNOLOGIAN TUTKIMUSKESKUS VTT OY | FI | 36 | 1.298.411,00 € |
| GALILEO | The first wide range flow sensor to unlock microfluidic cell analyses for preclinical studies | ELVESYS | FR | 24 | 1.667.500,00 € |
| MAG.NET | Magnetic neural Network for predictive maintenance | Golana Computing | FR | 36 | 2.500.000,00 € |
| MAGNIFY | Multi-lane, high-power Photonic Integrated Circuit-based Erbium-Doped Amplifier | LIGENTEC FRANCE | FR | 36 | 1.584.066,25 € |
| SMARTWAY | Nano meta components for electronic smart wireless systems | THALES | FR | 36 | 2.457.765,00 € |
| SPIN-ION | Hybrid Spintronic Synapses for Neuromorphic Computing | SPIN-ION TECHNOLOGIES | FR | 30 | 2.500.000,00 € |
| Crop4Clima | Resilient and environmentally sustainable engineered crops to address climate change | EVOGENE LTD | IL | 32 | 2.475.562,50 € |
| BIOPURE | Biopharmaceuticals purification by continuous membrane- assisted crystallization achieving lower cost and intensified processes | CONSIGLIO NAZIONALE DELLE RICERCHE | IT | 36 | 2.491.245,00 € |
| KEEPER | Key codE based on nanomatErials to Protect sErvices and pRoducts | POLITECNICO DI MILANO | IT | 30 | 2.111.146,25 € |
| PHIRE | Photoacoustic imaging and artificial intelligence-based theranostc approach for cancer | OSPEDALE SAN RAFFAELE SRL | IT | 36 | 2.471.021,25 € |
| PreBiomicsPMT | A metagenomic-based precision-medicine tool for personalized diagnosis, prognosis and treatment of oral diseases | PREBIOMICS SRL | IT | 36 | 2.461.900,00 € |
| ROBIOPSY | AI and Robotics for Prostate Biopsy | UNIVERSITA DEGLI STUDI DI VERONA | IT | 36 | 2.499.141,00 € |
| SILKink | Revolutionary silk-based bioink for 3D printing of ex vivo bone marrow models to advance drug development and personalized medicine | UNIVERSITA DEGLI STUDI DI PAVIA | IT | 36 | 2.494.687,50 € |
| Groove | Germanium quantum processors: more, robust, available | TECHNISCHE UNIVERSITEIT DELFT | NL | 24 | 2.500.000,00 € |
| LUMINODIN | A multipotent fluorescent tracer for imaging cancer lesions during surgery and follow up | ACADEMISCH ZIEKENHUIS LEIDEN | NL | 36 | 2.500.000,00 € |
| BIGALPS | Bio Inspired Geotechnical Applications to Launch Pan- European Solutions | UNIVERSITATEA TEHNICA CLUJ- NAPOCA | RO | 36 | 1.756.837,50 € |
| TOPFIBRO | Targeting OGG1 in Idiopathic Pulmonary Fibrosis | OXCIA AB | SE | 36 | 2.500.000,00 € |
| ENABLER | Tech and business validation towards market readiness of high-performance PFSA-free intermetallic Pt-alloy membrane electrode assemblies for PEMFCs: Enabling next- gen hydrogen-based transport | RECATALYST, RAZVOJ, PROIZVODNJA IN PRODAJA KATALIZATORSKIH KOMPOZITOV, D.O.O. | SI | 30 | 2.495.900,00 € |
| GENERA | A revolutionary, highly versatile drug delivery platform based on Metal-Organic Frameworks | Vector Bioscience Cambridge Ltd | UK | 36 | 2.498.082,00 € |
| IBDSENSE | Non-invasive technologies for diagnosis and monitoring of inflammatory bowel diseases | THE UNIVERSITY OF EDINBURGH | UK | 36 | 2.466.590,00 € |
Practical implications and final assessment
The EIC Transition awards are an important and predictable source of non-dilutive capital for mid-stage technology maturation across a wide set of strategic fields. They also reflect a policy aim to accelerate translation of EU-funded frontier research into products and companies that can contribute to Europe’s competitiveness in deep tech. That said, grant awards are an early milestone rather than an end point for commercialisation. Most projects will need to secure private follow-on capital, industrial partnerships, and regulatory approvals before they reach markets at scale. Observers and stakeholders should monitor the cohort for concrete outcomes in pilot deployments, industrial pilots, procurement wins or successful follow-on financing rounds as the real test of Transition effectiveness.
The EIC programme offers a more integrated path from high-risk research to market through its suite of instruments and the EIC Fund. Transition is a key component of that pipeline but does not remove the long lead times and systemic barriers inherent in deep tech commercialisation. For policy makers the challenge remains to complement grants and acceleration services with stronger mechanisms to crowd in private growth capital and to reduce regulatory and manufacturing bottlenecks for strategic technologies.

